①Multiple companies, including Jiehua Technology, have submitted listing applications in bulk. What are the highlights?
②GigaDevice’s stock surged nearly 70% in its first week of listing. Why is the market paying attention?
According to Livermore Securities, this week (January 12th to January 18th), 24 companies submitted listing applications to the Hong Kong Stock Exchange, three companies passed the hearing, one company started its initial public offering, and four new stocks were listed.
First, let’s look at the listing applications. A total of 24 companies submitted their IPO applications this week:
1) On January 12, Shenzhen Weizha Semiconductor Co., Ltd. submitted a listing application to the main board of the Hong Kong Stock Exchange, with GF Securities acting as its sponsor.
As disclosed in the prospectus,$Weizha Semiconductor (Temporary Code)(811057.HK)$is a leading Chinese provider of power semiconductor devices. In the medium- and low-voltage product categories, the company’s WLCSP products, known for their compact size, high heat dissipation performance, and strong shock resistance, are key components used in lithium battery protection applications such as smartphones, tablets, and wearable electronics. High-voltage products mainly include IGBTs, SJ MOSFETs, and Planar MOSFETs, designed to meet the demands for high voltage resistance, high power density, and reliability in harsh environments. These are widely used in automotive electronics, motor drives, and new energy applications.
In terms of financial performance, the company reported revenues of approximately RMB 575 million, RMB 624 million, and RMB 615 million for the fiscal years 2023, 2024, and the nine months ended September 30, 2025, respectively. During the same periods, net profits were approximately RMB 13.977 million, RMB 19.353 million, and RMB 40.254 million.
2) On January 12, Yuanji Food Group Co., Ltd. submitted a listing application to the main board of the Hong Kong Stock Exchange, with plans to list on the Hong Kong main board. Huatai International and GF Securities are acting as joint sponsors.
According to the prospectus,$Yuanji Foods (Temporary Code)(811058.HK)$the company owns the catering brand 'Yuanji Cloud Dumplings' and the retail brand 'Yuanji Flavor Enjoyment.' As of September 30, 2025, Yuanji Food operated 4,266 stores. The total GMV of these stores increased by 31% from RMB 4.772 billion in 2023 to RMB 6.248 billion in 2024. According to a relevant report by CIC灼识咨询, Yuanji Food is the largest Chinese fast-food chain by number of stores globally and the largest dumpling and wonton enterprise in China.
In terms of performance, Yuanji Food achieved revenues of RMB 2.026 billion and RMB 2.561 billion in 2023 and 2024, respectively, representing a year-on-year increase of 26%. For the first nine months of 2025, the adjusted net profit reached RMB 192 million, reflecting a year-on-year growth of 31%.
On January 12, Haida International Holdings Limited submitted its listing application to the Main Board of the Hong Kong Stock Exchange, with JPMorgan, CICC, and GF Securities acting as joint sponsors.
The prospectus shows that, $Haidar International (Temporary Code) (811059.HK)$Haida International is a technology-driven global agricultural enterprise, with feed business as its cornerstone, providing comprehensive integrated solutions across the entire value chain of the livestock industry. According to Frost & Sullivan, in 2024, the company ranked as the second-largest aquafeed supplier in Asia (excluding East Asia) by production volume.
In terms of financial performance, the company reported revenues of approximately RMB 9.025 billion, RMB 11.417 billion, and RMB 11.177 billion for the fiscal years 2023 and 2024, and the nine months ended September 30, 2025, respectively. The corresponding profits were approximately RMB 360 million, RMB 735 million, and RMB 869 million during the same periods.
On January 12, Hangzhou Boke Electronics Co., Ltd. submitted its listing application to the Main Board of the Hong Kong Stock Exchange, with China Merchants Securities International acting as the sole sponsor.
As disclosed in the prospectus,$Platinum Technology (Temporary Code) (811060.HK)$Boke Electronics is a global leader and the largest supplier of high-performance computing server power supplies in China, enabling a wide range of industrial, consumer, and commercial power conversion applications. According to Frost & Sullivan, based on revenue from high-performance computing server power supplies in 2024, the company held market shares of 8.9% globally and 18.9% in mainland China.
In terms of financial performance, the company recorded revenues of approximately RMB 261 million, RMB 556 million, and RMB 751 million for the fiscal years 2023 and 2024, and the nine months ended September 30, 2025, respectively. The corresponding profits were approximately RMB 4.237 million, RMB 39.601 million, and RMB 76.105 million during the same periods.
On January 13, Lianchi Hospital Group Co., Ltd. (referred to as Lianchi Hospital) submitted its listing application to the Main Board of the Hong Kong Stock Exchange, with China Galaxy International acting as the sole sponsor.
The prospectus shows that, $Lianchi Hospital (Temporary Code)(811061.HK)$is a Chinese specialty medical group focusing on premium healthcare services. According to Frost & Sullivan, in terms of the volume of knee-preserving surgeries performed by private hospitals in 2024, the company's Zibo Lianchi Orthopedic Hospital ranked first within Shandong Province and third nationwide. Based on Frost & Sullivan’s data, measured by revenue in 2024, the company's Chongqing Great Wall Orthopedic Hospital ranked first among private orthopedic specialty hospitals in Southwest China.
In terms of financial performance, the company reported revenues of approximately RMB 356 million, RMB 418 million, and RMB 359 million for the fiscal years 2023, 2024, and the nine months ended September 30, 2025, respectively. During the same periods, net profits were RMB 56.732 million, RMB 67.591 million, and RMB 55.514 million, respectively.
On January 13, Zhejiang Yifei Intelligent Technology Co., Ltd. (referred to as: Yifei Technology) submitted its listing application to the Main Board of the Hong Kong Stock Exchange, with ABCI serving as the sole sponsor.
The prospectus shows that, $Yifei Technology (Temporary Code)(810838.HK)$is a Chinese industrial robotics enterprise specializing in the design, research and development, manufacturing, and commercialization of industrial robots, while also providing comprehensive robotic solutions tailored for light industry applications. According to a Frost & Sullivan report, based on revenue in 2024, the company ranks fifth among domestic enterprises in China that focus on industrial robot solutions for light industry applications.
In terms of financial performance, the company achieved revenues of approximately RMB 162 million, RMB 201 million, RMB 268 million, and RMB 180 million for the fiscal years 2022, 2023, 2024, and the nine months ended September 30, 2025, respectively. During the same periods, net losses were RMB 58 million, RMB 110 million, RMB 71 million, and RMB 126 million, respectively.
On January 13, Henan Jinxing Beer Co., Ltd. submitted its listing application to the Main Board of the Hong Kong Stock Exchange, with CITIC Securities and BOCI acting as joint sponsors.
The prospectus shows that, $Jinxing Beer (Temporary Code)(811062.HK)$is a leading craft beer company dedicated to brewing beers with unique Chinese flavors. According to CIC灼识咨询, based on retail sales in 2024 and for the nine months ended September 30, 2025, the company ranked eighth in China's beer industry and fifth among domestic beer enterprises.
In terms of performance, the company's revenue for the nine months ended September 30, 2023, 2024, and 2025 was approximately RMB 356 million, RMB 730 million, and RMB 1.11 billion, respectively. The corresponding profits were approximately RMB 12.2 million, RMB 125 million, and RMB 305 million, respectively.
On January 13, Jiehuaot (688141.SH) submitted its listing application to the Main Board of the Hong Kong Stock Exchange, with CITIC Securities acting as its sole sponsor.
The prospectus shows that, $Jiehuaot (Provisional Code)(810780.HK)$The company operates as a virtual integrated device manufacturer ("IDM") in the field of analog integrated circuit ("IC") design, focusing on the research and development of analog ICs. According to Frost & Sullivan, in China’s analog IC market, Jiehuaot ranked 13th among all global analog IC companies by revenue in 2024, with a market share of 0.9%.
In terms of performance, the company’s revenue for the ten months ended October 31, 2022, 2023, 2024, and 2025 was approximately RMB 1.448 billion, RMB 1.297 billion, RMB 1.679 billion, and RMB 2.113 billion, respectively. The corresponding profits were a profit of RMB 136 million and losses of RMB 533 million, RMB 611 million, and RMB 496 million, respectively.
On January 13, Chengdu Zeling Biopharmaceutical Technology Co., Ltd. (referred to as "Zeling Bio") submitted its listing application to the Main Board of the Hong Kong Stock Exchange, with Jefferies and CICC acting as joint sponsors.
According to the prospectus,$Zeling Bio (Provisional Code)(811064.HK)$The company is a clinical-stage biotechnology firm dedicated to integrating structural biology, artificial intelligence, and clinically relevant disease models to develop highly differentiated small-molecule therapies with first-in-class or best-in-class potential. It has established a robust and diversified pipeline consisting of eight proprietary assets, spanning both clinical and preclinical stages.
In terms of performance, the company has not yet generated any revenue from product sales. For the year ended December 31, 2024, and the nine months ended September 30, 2025, the company’s other income and gains amounted to RMB 19.661 million and RMB 7.126 million, respectively. The corresponding losses were RMB 91.656 million and RMB 119 million, respectively.
On January 13, Shanghai Sunmi Technology Group Co., Ltd. submitted its listing application to the main board of the Hong Kong Stock Exchange, with Deutsche Bank, CITIC Securities, and ABC International acting as joint sponsors.
As disclosed in the prospectus,$Sunmi Technology-W (Temporary Code)(810810.HK)$is a globally leading provider of Business Internet of Things (BIoT) solutions. According to data from CIC, based on revenue in 2024, the company is currently the world's largest Android-based BIoT solution provider, holding more than 10% of the market share.
In terms of financial performance, the company’s revenues for the fiscal years 2022, 2023, 2024, and the nine months ended September 30, 2025, were approximately RMB 3.404 billion, RMB 3.071 billion, RMB 3.456 billion, and RMB 2.241 billion, respectively. During the same periods, profits were approximately RMB 160 million, RMB 101 million, RMB 181 million, and RMB 56.079 million, respectively.
On January 13, Shanghai Shengsheng Pharmaceutical Cold Chain Technology Co., Ltd. submitted its listing application to the main board of the Hong Kong Stock Exchange, with CICC and GF Securities (Hong Kong) acting as joint sponsors.
According to the prospectus,$Shengsheng Pharmaceutical (Temporary Code)(811065.HK)$is an integrated temperature-controlled supply chain service provider for the pharmaceutical and life sciences industries, focusing primarily on clinical trial temperature-controlled supply chain services while extending to medical product temperature-controlled supply chain services at the commercialization stage. According to a Frost & Sullivan report, calculated based on 2024 revenue, Shanghai Shengsheng is the largest temperature-controlled supply chain service provider for pharmaceuticals and life sciences in China and the only Chinese enterprise among the top ten global clinical trial temperature-controlled supply chain service providers.
In terms of financial performance, the company’s revenues for the fiscal years 2023, 2024, and the nine months ended September 30, 2025, were approximately RMB 614 million, RMB 654 million, and RMB 538 million, respectively; during the same periods, profits were approximately RMB 92.033 million, RMB 26.396 million, and RMB 113 million, respectively.
On January 14, Changzhou Juhé New Material Co., Ltd. submitted its listing application to the Hong Kong Stock Exchange, with Huatai International and Jefferies acting as joint sponsors.
According to the prospectus,$Juhematerial (Provisional Code)(811066.HK)$is a China-based advanced materials company driven by research and development. According to CIC Consulting, for the nine months ended September 30, 2025, the company ranked first in photovoltaic conductive paste sales revenue among all global photovoltaic conductive paste manufacturers. Its core business is the development and manufacturing of a comprehensive portfolio of photovoltaic conductive pastes suitable for different photovoltaic cell structures, including TOPCon, PERC, HJT, and X-BC.
In terms of performance, the company’s revenue has maintained a growth trend in recent years, increasing from RMB 10.23 billion in 2023 to RMB 12.39 billion in 2024, representing a year-on-year increase of 21.1%. For the first nine months of 2025, revenue reached RMB 10.61 billion, with a year-on-year growth of 9.9%. However, growth was primarily driven by price increases rather than volume expansion.
On January 14, Immvira Bioscience Inc. (EverNova Medicine) submitted an application for listing on the Main Board of the Hong Kong Stock Exchange, with Citi and CICC acting as its joint sponsors.
As disclosed in the prospectus,$EverNova Medicine-B (Provisional Code)(810811.HK)$is a biotech company focused on clinical demand-driven solutions, dedicated to the discovery, development, production, and commercialization of novel oncolytic immunotherapies and engineered exosome therapies. The company has built a product pipeline comprising: (i) two oncolytic immunotherapy products targeting solid tumors, and (ii) five engineered exosome products with promising clinical applications or direct commercial potential.
In terms of financial performance, the company recorded revenues of RMB 6.772 million, RMB 3.2 million, and RMB 1.305 million for the fiscal years 2023, 2024, and the nine months ended September 30, 2025, respectively. Corresponding net losses were RMB 482 million, RMB 524 million, and RMB 375 million during the same periods.
On January 14, Exegenesis Bio Inc. submitted an application for listing on the Main Board of the Hong Kong Stock Exchange, with CCB International serving as its exclusive sponsor.
According to the prospectus,Exegenesis Bio (provisional code)(811067.HK)is a biopharmaceutical company focused on gene therapies and oligonucleotide drugs. According to Frost & Sullivan, the company possesses world-leading delivery vector technology. Its core candidate product, EXG001-307 (SMA Type 1), is expected to become the best-in-class treatment for Spinal Muscular Atrophy (SMA) Type 1. Additionally, it has two key candidate products: EXG102-031 (an AAV-based gene therapy for treating wet age-related macular degeneration (wAMD)) and EXG202 (an AAV-based gene therapy for treating fundus neovascular diseases, including wAMD, diabetic macular edema (DME), and retinal vein occlusion (RVO)).
In terms of performance, none of the company's pipeline candidates have received regulatory or commercial approval. For the fiscal year ended December 31, 2024, the company reported no revenue. For the nine months ended September 30, 2025, revenue amounted to RMB 1.299 million, with losses of RMB 220 million and RMB 94 million during the same period.
On January 15, Estun submitted its listing application to the Main Board of the Hong Kong Stock Exchange, with Huatai International acting as the exclusive sponsor.
The prospectus shows that, according to Frost & Sullivan, in terms of revenue,Estun (provisional code)(810822.HK)also ranks first among industrial robotics companies. Based on 2024 revenue, Estun ranked sixth globally and in the Chinese market among all manufacturers, with market shares of 1.7% and 2.0%, respectively.
In terms of financial performance, the company reported revenues of approximately RMB 3.881 billion, RMB 4.652 billion, RMB 4.009 billion, and RMB 3.804 billion for the years 2022, 2023, 2024, and the nine months ended September 30, 2025, respectively. Corresponding profits were RMB 1.84 billion, RMB 1.34 billion, -RMB 8.18 billion, and RMB 0.3 billion.
On January 16, Tosun submitted its listing application to the Main Board of the Hong Kong Stock Exchange, with Huatai International acting as the exclusive sponsor.
According to the prospectus,Tosida (300607.SZ)is the leader in the full-stack industrial robotics industry in mainland China. In 2024, Tosida ranked first in the mainland China industrial robot solutions market by both lightweight load industrial robot shipments and industrial robot shipments in the light industry sector.
In terms of financial performance, for 2023, 2024, and the first nine months of 2025, the company's revenue was RMB 4.553 billion, RMB 2.872 billion, and RMB 1.688 billion, respectively. Net profit for the same periods was RMB 0.088 billion, -RMB 0.245 billion, and RMB 0.047 billion, respectively.
On January 16, Guangzhou Onyx Information Technology Co., Ltd. submitted its listing application to the Hong Kong Stock Exchange on the same day, with CITIC Securities International serving as the sole sponsor.
The prospectus shows that Guangzhou Onyx Information Technology is a company specializing in the research, design, and sales of e-reading devices, with its flagship product being the Boox series of e-readers. Its BOOX series of smart ink screen tablets have become one of the mainstream e-readers globally.
In terms of financial performance, for 2023, 2024, and the first nine months of 2025, revenue was RMB 0.804 billion, RMB 1.018 billion, and RMB 0.8 billion, respectively; net profits were RMB 0.124 billion, RMB 0.121 billion, and RMB 0.103 billion, respectively.
On January 16, Xiamen Ruiyunlian Innovation Technology Co., Ltd. submitted its listing application to the Main Board of the Hong Kong Stock Exchange, with CMB International serving as the sole sponsor.
According to the prospectus, based on Frost & Sullivan data, by shipment volume in 2024, Ruiyunlian is the largest provider of smart intercom solutions in North America and Europe. As of September 30, 2025, the cumulative global sales of the company's smart community solutions were approximately two million units. As of the same date, Ruiyunlian's cloud services had cumulatively covered more than 530,000 households, ranking second globally in terms of household coverage.
In terms of financial performance, for 2023, 2024, and the nine months ended September 30, 2025, revenue was approximately RMB 0.274 billion, RMB 0.347 billion, and RMB 0.278 billion, respectively; net profits for the same periods were approximately RMB 38.175 million, RMB 53.438 million, and RMB 44.573 million, respectively.
On January 16, QinHao Pharmaceuticals (Suzhou) Co., Ltd. submitted its listing application to the Main Board of the Hong Kong Stock Exchange, with Huatai International serving as the exclusive sponsor.
According to the prospectus, GenHouse Pharma is a biopharmaceutical company with a differentiated and robust pipeline of innovative drug candidates developed in-house, focusing on the RAS signaling pathway and synthetic lethality mechanisms. According to CIC data, in terms of clinical progress for the same target, multiple candidate drugs from the company are globally leading.
In terms of financial performance, the company's revenue for the fiscal year 2024 and the first nine months of 2025 was RMB 4.69 million and RMB 0.981 million, respectively, with corresponding losses of RMB 152 million and RMB 99 million during the same periods.
On January 16, Yunfeng Moganshan Eco-Home Co., Ltd. submitted its listing application to the Main Board of the Hong Kong Stock Exchange, with CITIC Securities acting as its sponsor.
According to the prospectus, the company is a comprehensive green home service provider, mainly offering green man-made boards and customized green home products and services. It also licenses intellectual property (including product design, trademarks, and production processes) to qualified OEM partners while providing value-added services such as training, technical support, quality control, and marketing to distributors and OEM partners.
In terms of financial performance, Moganshan Home's revenue for the fiscal years 2023, 2024, and the first three quarters of 2025 was RMB 3.394 billion, RMB 3.456 billion, and RMB 2.519 billion, respectively; net profits for the same periods were RMB 320 million, RMB 321 million, and RMB 280 million, respectively.
On January 16, Harbin Yuyantang Traditional Chinese Medicine Clinic Group Co., Ltd. submitted its listing application to the Main Board of the Hong Kong Stock Exchange, with CMB International and Guoyuan International acting as joint sponsors.
According to a Frost & Sullivan report, in terms of total revenue from traditional Chinese medicine clinics and medical centers in 2024, Yuyantang ranked second among private chain TCM healthcare providers in northern China. In terms of ointment revenue, Yuyantang ranked first. Based on high patient trust, Yuyantang's customer repurchase rate ranked first among private chain TCM healthcare providers in 2024.
In terms of financial performance, the company's revenue for the fiscal years 2023, 2024, and the first nine months of 2025 was RMB 150 million, RMB 215 million, and RMB 284 million, respectively; corresponding profits were RMB 20 million, RMB 27 million, and RMB 55 million during the same periods.
On January 16, Big Pizza International Holdings Limited submitted its listing application to the Main Board of the Hong Kong Stock Exchange, with BOC International acting as its exclusive sponsor.
According to CIC data, based on GMV for the nine months ended September 30, 2025, the company ranked first among local pizza restaurants in China, with a gross merchandise value of RMB 1.7 billion and a market share of 4.3%. During the same period, it ranked first among buffet restaurants with a market share of 1.2% and also ranked first among Western casual dining restaurants.
In terms of performance, the company achieved revenue of approximately RMB 943 million, RMB 1.147 billion, RMB 833 million, and RMB 1.389 billion for the fiscal years 2023 and 2024, the nine months ended September 30, 2024, and the nine months ended September 30, 2025, respectively. Net profits during these periods were approximately RMB 47.518 million, RMB 41.737 million, RMB 32.425 million, and RMB 51.651 million, respectively.
On January 16, Shandong Huawutang Cosmetics Co., Ltd. submitted its listing application to the Main Board of the Hong Kong Stock Exchange, with CITIC Securities acting as its sole sponsor.
The prospectus shows that the company is a Chinese skin and personal care brand that has distinguished itself in the industry due to continuous high-speed growth and multi-category expansion. Starting from a single star product, it gradually expanded into a full-category matrix covering body, hair, and facial care. According to Frost & Sullivan, in terms of retail sales in 2024, the company ranked first among domestic brands in body lotion, body scrubs, and facial cleansing mousses.
In terms of financial performance, Huawutang achieved revenue of RMB 1.199 billion and RMB 1.499 billion in 2023 and 2024, respectively, with adjusted net profits of RMB 23.7 million and RMB 82.8 million, respectively.
On January 16, Shanghai Maxin Health Technology Group Co., Ltd. submitted its listing application to the Main Board of the Hong Kong Stock Exchange, with Goldman Sachs, CICC, and HSBC serving as joint sponsors.
According to the prospectus,$Maxin Health (Temporary Code)(810841.HK)$Founded in 2017, the company is China's largest pharmaceutical multi-payment platform. As of October 31, 2025, Maxin Health had cumulatively served approximately 2 million patients, involving medical expenditure GPV of RMB 50.2 billion; more than 100 insurance companies, including all of China's top 20 insurers by premium income in 2024; and over 140 pharmaceutical enterprises, including 90% of the global top 20 by revenue in 2024.
In terms of financial performance, the company reported revenues of RMB 1.069 billion, RMB 1.255 billion, and RMB 2.035 billion in 2022, 2023, and 2024, respectively. Annual losses were RMB 446 million, RMB 288 million, and RMB 75.77 million, respectively.
Turning to listing hearings, two companies passed the listing hearing this week:
On January 14, Guoen Shares passed the listing hearing for the Main Board of the Hong Kong Stock Exchange, with CMB International acting as the sole sponsor.
According to the prospectus,$Guoen Shares (Temporary Code)(810815.HK)$is a Chinese supplier specializing in chemical new materials and gelatin and collagen products across the upstream and downstream supply chain. According to Frost & Sullivan, in 2024, measured by revenue, Guoen Shares ranked as the second-largest enterprise in China’s organic polymer modified materials and organic polymer composite materials sector, with a market share of 2.5%. Additionally, in 2024, the company ranked as the largest polystyrene enterprise in China by production capacity.
In terms of financials, for the fiscal years 2022, 2023, 2024, and the first ten months of fiscal year 2025, Guoen Shares reported revenues of approximately RMB 13.406 billion, RMB 17.439 billion, RMB 19.188 billion, and RMB 17.444 billion, respectively. During the same periods, profits were RMB 724 million, RMB 540 million, RMB 721 million, and RMB 721 million, respectively.
On January 14, Eastroc Beverage passed the listing hearing for the Main Board of the Hong Kong Stock Exchange, with Huatai International, Morgan Stanley, and UBS Group acting as joint sponsors.
The prospectus shows that, $Eastroc Beverage (Temporary Code) (810720.HK)$is the leading functional beverage enterprise in China, with revenue growth ranking first among the top 20 publicly listed global soft drink companies. According to the Frost & Sullivan report, measured by sales volume, the company ranked first in China’s functional beverage market for four consecutive years starting from 2021. Measured by retail value, the company was the second-largest functional beverage enterprise in 2024, with a market share of 23%.
In terms of financials, for the fiscal years 2022, 2023, 2024, and the nine months ended September 30 of fiscal years 2024 and 2025, Eastroc Beverage reported revenues of approximately RMB 8.5 billion, RMB 11.257 billion, RMB 15.83 billion, RMB 12.552 billion, and RMB 16.838 billion, respectively. During the same periods, total profits were approximately RMB 1.426 billion, RMB 2.059 billion, RMB 3.364 billion, RMB 2.699 billion, and RMB 3.71 billion, respectively.
On January 16, Muyuan Shares passed the listing hearing for the Main Board of the Hong Kong Stock Exchange, with Morgan Stanley, CITIC Securities, and Goldman Sachs acting as joint sponsors.
The prospectus shows that, $Muyuan Shares (Temporary Code) (810765.HK)$As a leader in the hog farming industry, according to Frost & Sullivan statistics, since 2021, the company has been the world's largest hog farming enterprise in terms of hog production capacity and output, with its hog output ranking first globally for four consecutive years.
In terms of financial performance, for the fiscal years 2022, 2023, 2024, as well as the nine months ended September 30, 2024, and 2025, Muyuan Foods reported revenues of approximately RMB 124.826 billion, RMB 110.861 billion, RMB 137.947 billion, RMB 96.775 billion, and RMB 111.790 billion, respectively; during the same periods, net profits were approximately RMB 14.933 billion, -RMB 4.168 billion, RMB 18.925 billion, RMB 11.246 billion, and RMB 15.112 billion, respectively.
In terms of IPOs, one additional company is conducting an offering this week.
1）$Longcheer Technology (09611.HK)$The offering will take place from January 14 to January 19, 2026. The company plans to offer 52,259,100 H-shares globally, with 10% allocated for the Hong Kong offering and 90% for international placement. The maximum issue price per share will be HKD 31.00, and each trading lot for H-shares will consist of 100 shares. Trading of the H-shares on the Stock Exchange is expected to commence at 9:00 AM on Thursday, January 22, 2026.
Additionally, four new stocks will be listed this week.
On January 12,OmniVision Group (00501.HK)The stock rose 16.22% on its first day of listing, then experienced fluctuations before stabilizing, ending the first week with an increase of only 8.02% over the issue price, reflecting moderate performance as a leading global image sensor supplier.
On January 13,$Red Star Cold Chain (01641.HK)$The stock increased by 0.33% on its debut day, followed by a downward fluctuation in subsequent days, resulting in a cumulative decline of 8.65% in the first week. As a traditional logistics company, it garnered relatively low market attention.
On January 13,$BBSB INTL(08610.HK)$The stock gained 11.67% on its first trading day, followed by sideways fluctuations in the subsequent days, ending the first week with a cumulative gain of 10%.
On January 13,GigaDevice (03986.HK)The stock surged 37.53% on its first day of listing, followed by upward fluctuations in the subsequent days, culminating in a cumulative rise of 67.90% in the first week. Benefiting from the current high demand in the storage industry, it became the most outstanding-performing new stock of the week.
Use Futu for new stock subscriptions, with truly zero interest, zero handling fees, and zero cash subscription*. Get ahead in the grey market trading.Come and experience it now >>
Editor/Melody
